Trial
NCT00602745
S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sanofi
Collaborators
Taiho Pharmaceutical Co., Ltd.
Condition
Pancreatic Neoplasm
Intervention
S-1
Why stopped
Following the termination of development and commercialization agreement for S-1 with Taiho Pharmaceutical
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-05-26